Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Company Overview - Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs [1][5] - The company is advancing its late-stage drug candidate ALXN1840 for Wilson disease, along with several radiopharmaceutical programs [5] Market Inclusion - Monopar will be added to the Russell 3000® Index and automatically included in the small-cap Russell 2000® Index after the close of U.S. equity markets on June 27, 2025 [1][2] - This inclusion is part of the annual reconstitution of the Russell U.S. Indexes, which are widely used benchmarks for investment strategies [2][3] Financial Impact - As of May 2025, approximately $10.6 trillion in assets are benchmarked against the Russell U.S. Indexes, indicating significant market influence [3] - The inclusion in these indexes is expected to enhance Monopar's visibility and recognition in the market, reflecting the company's growth and transformation over the past year [4]